These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 26121111)
41. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
42. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Chakupurakal G; Freudenberger P; Skoetz N; Ahr H; Theurich S Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009159. PubMed ID: 37341189 [TBL] [Abstract][Full Text] [Related]
43. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970 [TBL] [Abstract][Full Text] [Related]
44. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience. Zhou L; Gao ZY; Lu DP Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495 [TBL] [Abstract][Full Text] [Related]
45. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Baron F; Zachée P; Maertens J; Kerre T; Ory A; Seidel L; Graux C; Lewalle P; Van Gelder M; Theunissen K; Willems E; Emonds MP; De Becker A; Beguin Y J Hematol Oncol; 2015 Feb; 8():4. PubMed ID: 25652604 [TBL] [Abstract][Full Text] [Related]
46. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504 [TBL] [Abstract][Full Text] [Related]
47. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH; Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363 [TBL] [Abstract][Full Text] [Related]
48. Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia. Chen X; Wei J; Huang Y; He Y; Yang D; Zhang R; Jiang E; Ma Q; Zhai W; Yao J; Zhang G; Feng S; Han M Biol Blood Marrow Transplant; 2018 Jan; 24(1):86-90. PubMed ID: 29032265 [TBL] [Abstract][Full Text] [Related]
49. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Kuriyama K; Fuji S; Inamoto Y; Tajima K; Tanaka T; Inoue Y; Ito R; Hayashi Y; Ito A; Kurosawa S; Kim SW; Yamashita T; Fukuda T Int J Hematol; 2016 Apr; 103(4):453-60. PubMed ID: 26857285 [TBL] [Abstract][Full Text] [Related]
50. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Admiraal R; Nierkens S; de Witte MA; Petersen EJ; Fleurke GJ; Verrest L; Belitser SV; Bredius RGM; Raymakers RAP; Knibbe CAJ; Minnema MC; van Kesteren C; Kuball J; Boelens JJ Lancet Haematol; 2017 Apr; 4(4):e183-e191. PubMed ID: 28330607 [TBL] [Abstract][Full Text] [Related]
51. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG]. Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903 [TBL] [Abstract][Full Text] [Related]
52. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. Malard F; Labopin M; Cho C; Blaise D; Papadopoulos EB; Passweg J; O'Reilly R; Forcade E; Maloy M; Volin L; Castro-Malaspina H; Hicheri Y; Jakubowski AA; Orvain C; Giralt S; Mohty M; Nagler A; Perales MA J Hematol Oncol; 2018 Oct; 11(1):127. PubMed ID: 30342553 [TBL] [Abstract][Full Text] [Related]
54. Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Remberger M; Mattsson J; Ringdén O Pediatr Transplant; 2001 Aug; 5(4):285-92. PubMed ID: 11472608 [TBL] [Abstract][Full Text] [Related]
55. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin). Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kanda Y Hematology; 2017 Apr; 22(3):129-135. PubMed ID: 27905258 [TBL] [Abstract][Full Text] [Related]
56. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Mohty M; Labopin M; Balère ML; Socié G; Milpied N; Tabrizi R; Ifrah N; Hicheri Y; Dhedin N; Michallet M; Buzyn A; Cahn JY; Bourhis JH; Blaise D; Raffoux C; Espérou H; Yakoub-Agha I Leukemia; 2010 Nov; 24(11):1867-74. PubMed ID: 20882046 [TBL] [Abstract][Full Text] [Related]
57. Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies. Li Q; Meng F; Zhou M; Yu B; Mo W; Du Q; Jiang X; Wei Y Med Sci Monit; 2015 Aug; 21():2257-65. PubMed ID: 26238068 [TBL] [Abstract][Full Text] [Related]
58. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687 [TBL] [Abstract][Full Text] [Related]
59. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052 [TBL] [Abstract][Full Text] [Related]
60. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease]. Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]